Chevron's Q1 Output Surges on Hess Deal, but Negative FCF Raises Questions

What happened

Chevron's first-quarter U.S. production jumped 24% year-on-year, fueled by the Hess acquisition's contribution, and the company returned $6 billion to shareholders through $2.5 billion in buybacks and $3.5 billion in dividends. However, the underlying cash flow story is weaker: operating cash flow halved to $2.5 billion from $5.2 billion a year earlier, leading to negative free cash flow of -$1.5 billion as capex rose. The DeepValue report flags that this cash shortfall was plugged by drawing down cash and increasing commercial paper, pushing total debt to $45.4 billion from $40.8 billion at year-end. Management expects the $2.9 billion adverse timing effects and Tengiz downtime to normalize, but the report's “WAIT” rating demands hard evidence of recovery before buying. For now, the stock at $182.7 prices in a return to normal that has not yet arrived, leaving the risk-reward tilted toward waiting for Q2 confirmation.

Implication

The headline production and return numbers are superficially positive, but the 1Q26 cash-flow details show a company borrowing to sustain distributions. The DeepValue report positions CVX as a “WAIT” because the next quarter must demonstrate that timing effects unwind, Tengiz stays operational, and buybacks hit the $2.5B–$3.0B guided range. If those confirmations arrive, the distribution model is credible and the 9.8x EV/EBITDA offers upside toward $215. If not, the equity faces a reset risk, with a bear case at $150 if cash flow stays negative and debt keeps rising. At a 33x P/E, the valuation already embeds optimism, making it prudent to wait for tangible evidence before committing capital.

Thesis delta

The DeepValue master report maintains its WAIT stance on CVX, emphasizing that the Q1 beat on production and returns is not sufficient to justify buying at current levels. The thesis shift is one of timing: the news confirms production synergy from Hess, but the cash conversion is worse than expected, requiring at least one more quarter of data to validate the self-funding distribution model. Until then, the risk-reward favors patience over action.